破发股南新制药股东拟减持 上市募资12亿西部证券保荐

Core Viewpoint - Guangzhou Qianyuan Investment Consulting Partnership plans to reduce its stake in Nanxin Pharmaceutical due to funding needs, with a total reduction not exceeding 8,232,000 shares, representing 3.00% of the company's total share capital [1][2]. Group 1: Share Reduction Plan - The reduction will occur through centralized bidding and block trading within three months after the announcement, starting from 15 trading days post-announcement [1]. - The maximum number of shares to be reduced via centralized bidding is 2,744,000 shares, with a limit of 1% of the total share capital within any consecutive 90-day period [1]. - The maximum number of shares to be reduced via block trading is 5,488,000 shares, with a limit of 2% of the total share capital within any consecutive 90-day period [1]. Group 2: Shareholder Information - As of the announcement date, Guangzhou Qianyuan holds 43,120,000 shares, accounting for 15.71% of the total share capital [2]. - The shares held include 22,000,000 shares acquired before the IPO, 8,800,000 shares from capital reserve conversion in 2021, and 12,320,000 shares from capital reserve conversion in 2022 [2]. Group 3: Company Background - Nanxin Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on March 26, 2020, with an initial offering price of 34.94 yuan per share [3]. - The total funds raised from the IPO amounted to 1.223 billion yuan, with a net amount of 1.135 billion yuan, exceeding the original target by 466 million yuan [3]. - The company incurred total issuance costs of 87.6177 million yuan, with underwriting fees to the lead underwriter, Western Securities, totaling 71.1075 million yuan [3].